Association of Low-Dose Triple Combination Therapy With Therapeutic Inertia and Prescribing Patterns in Patients With Hypertension

作者：Nelson Wang, Abdul Salam, Ruth Webster, Asita de Silva, Rama Guggilla, Sandrine Stepien, Jayanthi Mysore, Laurent Billot, Stephen Jan, Pallab K Maulik, Nitish Naik, Vanessa Selak, Simon Thom, Dorairaj Prabhakaran, Anushka Patel, Anthony Rodgers, TRIUMPH Study Group · 发表于：JAMA Cardiology · 年份：2020 · DOI：10.1001/jamacardio.2020.2739 · 被引用次数：34 · 研究领域：Blood Pressure and Hypertension Studies、Medication Adherence and Compliance、Heart rate and cardiovascular health

Importance: Fixed-dose combination (FDC) therapies are being increasingly recommended for initial or early management of patients with hypertension, as they reduce treatment complexity and potentially reduce therapeutic inertia. Objective: To investigate the association of antihypertensive triple drug FDC therapy with therapeutic inertia and prescribing patterns compared with usual care. Design, Setting, and Participants: A post hoc analysis of the Triple Pill vs Usual Care Management for Patients With Mild-to-Moderate Hypertension (TRIUMPH) study, a randomized clinical trial of 700 patients with hypertension, was conducted. Patients were enrolled from 11 urban hospital clinics in Sri Lanka from February 2016 to May 2017; follow-up ended in October 2017. Data were analyzed from September to November 2019. Interventions: Once-daily FDC antihypertensive pill (telmisartan, 20 mg; amlodipine, 2.5 mg; and chlorthalidone, 12.5 mg) or usual care. Main Outcomes and Measures: Therapeutic inertia, defined as not intensifying therapy in those with blood pressure (BP) above target, was assessed at baseline and during follow-up visits. Prescribing patterns were characterized by BP-lowering drug class and treatment regimen potency. Predictors of therapeutic inertia were assessed with binomial logistic regression. Results: Of the 700 included patients, 403 (57.6%) were female, and the mean (SD) age was 56 (11) years. Among patients who did not reach the BP target, therapeutic inertia was mo...